Sugammadex + Neostigmine
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postoperative Complications
Conditions
Postoperative Complications, Neuromuscular Blockade
Trial Timeline
Jan 24, 2017 → Apr 30, 2018
NCT ID
NCT02861131About Sugammadex + Neostigmine
Sugammadex + Neostigmine is a approved stage product being developed by Merck for Postoperative Complications. The current trial status is completed. This product is registered under clinical trial identifier NCT02861131. Target conditions include Postoperative Complications, Neuromuscular Blockade.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04546672 | Approved | Completed |
| NCT03276026 | Approved | Terminated |
| NCT03112993 | Approved | Completed |
| NCT02861131 | Approved | Completed |
| NCT02909439 | Approved | Completed |
| NCT01050543 | Phase 3 | Completed |
| NCT00825812 | Phase 3 | Completed |
| NCT00451217 | Phase 3 | Completed |
| NCT00451100 | Phase 3 | Completed |
Competing Products
20 competing products in Postoperative Complications